|
MaxCyte Inc on Thursday said it has signed a strategic platform license with Lyell Immunopharma Inc, a clinical stage T cell reprogramming company. The cell-engineering technology platform based in Maryland, US said that under the terms of the agreement, Lyell Immunopharma obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation technology and ExPert platform. In return, MaxCyte is eligible to receive platform licensing fees, clinical milestone payments and sales-based payments. ‘MaxCyte’s ExPert instrument portfolio is the next generation of leading, clinically-validated electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPert platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics,’ the company explained. MaxCyte did not disclose financial details of the deal, but said each of its strategic partnerships generate pre-commercial milestone revenue and the vast majority include sales-based payments. ‘At MaxCyte, our goal is to maximize the potential of cells to improve patients’ lives, and it is through collaborations such as this that we can achieve success,’ said Chief Executive Officer Doug Doerfler. ‘We look forward to supporting Lyell Immunopharma in its development of solid tumour treatments for patients with unmet needs.’ Shares in MaxCyte were up 1.9% to 351.65 pence each in London on Thursday afternoon. Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
